A Study Evaluating the Efficacy and Safety of SYH2072 Tablets In Hypertensive Patients

Inclusion Criteria:

1. Voluntarily participate in this study and sign the informed consent form.
2. Age ≥ 18 years at the time of screening, male or female.
3. Mean seated systolic blood pressure (msSBP) at screening was ≥140 mmHg and <180 mmHg.
4. During the run-in period, adherence to baseline antihypertensive medications and study medications ranged from 80% to 120% (including the boundary values);
5. There were no changes in the types or doses of baseline antihypertensive medications prior to randomization, and no rescue therapy was administered.

Exclusion Criteria:

1. Known causes of secondary hypertension: renal artery stenosis, primary aldosteronism, Cushing's syndrome, pheochromocytoma, aortic coarctation, etc.;
2. Allergic constitution (allergies to ≥3 types/classes of drugs or foods); or known allergy to aldosterone synthase inhibitors or background antihypertensive medications;
3. History of malignancy within the past 5 years, or a potential malignancy currently under evaluation;
4. Type 2 diabetes with poor glycemic control, unstable antidiabetic treatment regimens within 4 weeks prior to screening, or type 1 diabetes;
5. Hyperthyroidism or hypothyroidism requiring immediate treatment or medication adjustment; or subclinical hypothyroidism with a TSH level >10.0 mIU at screening or requiring medication as assessed by the investigator;
6. Severe cardiovascular or cerebrovascular disease within 6 months prior to screening;
7. Individuals who plan to conceive (including through sperm or egg donation) from the signing of the ICF until 3 months after the last dose of the investigational drug, and/or who do not agree to use effective non-pharmacological contraception;
8. Pregnant or breastfeeding women.